Vicuron About
Vicuron Vicuron Pharmaceuticals is an international biopharmaceutical
company focused on discovering, developing, manufacturing and commercializing
vital medicine for seriously ill patients. The company's lead products are in
Phase III clinical trials and include anidulafungin, a novel antifungal
agent, and dalbavancin, a novel intravenous antibiotic for the treatment
of serious Gram-positive infections. Dalbavancin,
is a next-generation antibiotic belonging to the same class as vancomycin,
one of the most widely used injectable antibiotics for Staphylococcal
infections. Anidulafungin -- anti-fungal
Dalbavancin -- glycopeptide class of antibiotics
(hospital infections) Oxazolidinones -- most-difficult-to-treat,
multi-drug-resistant bacteria Deformylase Inhibitors --antibiotic
-- respiratory tract infections More
on Vicuron